Share on StockTwits

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating restated by Zacks in a note issued to investors on Thursday. They currently have a $69.00 price target on the stock. Zacks‘s price target would suggest a potential upside of 5.60% from the company’s current price.

Zacks’ analyst wrote, “Alnylam’s second-quarter 2014 loss of $0.63 per share was wider than the Zacks Consensus Estimate of a loss of $0.54 as well as the year-ago loss of $0.29. We are encouraged by Alnylam’s progress with its pipeline, especially the ATTR program. Meanwhile, Alnylam’s deal with Sanofi has ensured continued pipeline progress apart from boosting Alnylam’s balance sheet. With multiple data read-outs expected in the coming months, we expect the remainder of 2014 to be data rich for the company. However, any negative news related to the pipeline will weigh heavily on the stock. We see limited upside potential from current levels and hence maintain our Neutral stance on Alnylam.”

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 0.83% during mid-day trading on Thursday, hitting $65.88. 374,334 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a one year low of $46.72 and a one year high of $112.57. The stock’s 50-day moving average is $58.14 and its 200-day moving average is $64.75. The company’s market cap is $5.030 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. The company had revenue of $7.30 million for the quarter, compared to the consensus estimate of $9.36 million. During the same quarter last year, the company posted ($0.29) earnings per share. Alnylam Pharmaceuticals’s revenue was down 16.0% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals will post $-5.37 EPS for the current fiscal year.

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.